A Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers
13 juli 2026 bijgewerkt door: RAI Services Company
A Multi-Site Two-Arm Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Combustible Cigarette Smokers
The goal of this study is to evaluate the rate of end of study complete cigarette reduction in health adult consumers of cigarettes when given access to a heated tobacco product (HTP).
The primary study objective is to evaluate the impact of access to HTP Device 1 or HTP Device 2 and a single stick variant on the rate of final 7-day abstinence from smoking cigarettes among U.S. adult smokers at the end of a 3-month study period.
Studie Overzicht
Toestand
Werving
Interventie / Behandeling
Gedetailleerde beschrijving
This will be a multi-site, open-label, two-arm study to evaluate the rate of end of study complete combustible cigarette (CC) reduction in healthy adult consumers of CC when given access to a heated tobacco product (HTP) device (glo or glo plus), with one of four variants of HTP consumables (also known as "sticks" or "stick variants", under the brand name "virto") over a 3-month (90-day) actual use period (AUP).
Studietype
Ingrijpend
Inschrijving (Geschat)
1060
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Emily Smith
- Telefoonnummer: 336-741-2396
- E-mail: smithe13@rjrt.com
Studie Locaties
-
-
Florida
-
Brandon, Florida, Verenigde Staten, 33511
- Werving
- Opinions Brandon
-
Coral Springs, Florida, Verenigde Staten, 33071
- Werving
- Opinions Coral Springs
-
-
Illinois
-
Aurora, Illinois, Verenigde Staten, 60504
- Werving
- Opinions Chicago
-
Gurnee, Illinois, Verenigde Staten, 60031
- Werving
- Opinions Chicago
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89107
- Werving
- Opinions Las Vegas
-
Las Vegas, Nevada, Verenigde Staten, 89119
- Werving
- Opinions Las Vegas
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76132
- Werving
- Opinions Fort Worth
-
Houston, Texas, Verenigde Staten, 77070
- Werving
- Opinions Houston
-
Hurst, Texas, Verenigde Staten, 76053
- Werving
- Opinions Dallas
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Ja
Beschrijving
Inclusion Criteria:
- Able to read, understand, and are willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English.
- Generally healthy male or female, between 21 and 65 years of age, inclusive, at the time of consent, verified with government-issued identification.
- All female (assigned at birth) candidate participants who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant. Note: Participants who identify as "intersex" or "unknown" during screening, will be required to take a pregnancy test if they wish to take one.
- Currently smoke at least five combustible cigarettes on smoking days in the past 30 days.
- Smoke combustible cigarettes on 15 or more of the past 30 days.
- Smoked at least 100 factory-made filtered menthol and/or non-menthol combustible cigarettes in their lifetime prior to the Site Enrollment Visit.
- Must indicate a neutral/positive intention to use at least one stick variant at the Site Enrollment Visit.
- Own a smartphone (iOS or Android) with internet access to download a study application to access surveys and the capability to receive notifications.
- Agree to participate in the study and to abide by the study restrictions and requirements, as described in the ICF.
- Must try all four stick variants during the 1-week product trial period.
- Must indicate a neutral/positive intention to use at least one stick variant following the product trial period.
Exclusion Criteria:
- Female participants who are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months based on self-report.
- Male participants who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or refrain from donating sperm from the time of the signing of the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Female participants who self-report not using adequate methods to prevent pregnancy.
- Persons with pacemakers or other embedded electronic medical devices fitted.
- Participants who self-report having an unstable heart condition, severe hypertension, or diabetes.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Participants who have used electronic nicotine delivery system (ENDS), nicotine pouches, HTP or smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, other combustible tobacco/nicotine products, and other oral nicotine products (tablets, gums, and lozenges) on 5 or more days in the past 30 days.
- Participants who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Employee of a company that manufactures tobacco or HTPs.
- Persons who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or HTPs.
- Have taken part in a tobacco/nicotine research study in the past 30 days.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: HTP Device 1
HTP Device (One Piece) with two menthol and two tobacco stick variants
|
Tobacco Flavor #1
Tobacco Flavor #2
Menthol #1
Menthol #2
|
|
Actieve vergelijker: HTP Device 2
HTP Device (Two Piece) with two menthol and two tobacco stick variants
|
Tobacco Flavor #1
Tobacco Flavor #2
Menthol #1
Menthol #2
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Number and proportion of participants self-reporting past 7-day complete combustible cigarette reduction (abstinence) during the final 7 days of the 3-month (90-day) study period in each study arm and by stick variant within the study arm.
Tijdsspanne: 7 days
|
7 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The number and proportion of participants who completely switch from combustible cigarette smoking to HTP device 1 or HTP device 2 during the entire final 7 days of the 3 month study period in each study arm and by stick variant within the study arm.
Tijdsspanne: 7 days
|
7 days
|
|
The number and proportion of participants who reduce their combustible cigarettes by more than or equal to 50% within their average weekly cigarettes per day from baseline to final 7 days of the study period in each study arm and by stick variant.
Tijdsspanne: 3 months
|
3 months
|
|
The time to first 7-day abstinence of combustible cigarettes by participants in each study arm and by stick variant within each study arm
Tijdsspanne: 3 months
|
3 months
|
|
The weekly mean percent cigarettes per day reductions from baseline in each study arm and by stick variant within each arm
Tijdsspanne: 3 months
|
3 months
|
|
The number and type of adverse experiences/events in relation to use of the Study IP in each study arm and by stick variant within each study arm
Tijdsspanne: 3 months
|
3 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 juli 2026
Primaire voltooiing (Geschat)
1 december 2026
Studie voltooiing (Geschat)
1 december 2026
Studieregistratiedata
Eerst ingediend
13 juli 2026
Eerst ingediend dat voldeed aan de QC-criteria
13 juli 2026
Eerst geplaatst (Werkelijk)
17 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
17 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
13 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PHI252504
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .